Navigation Links
Bone Marrow Cancer Patients May Benefit From Drug Combo
Date:3/29/2010

Small study had successful results in myelodysplastic syndrome patients

MONDAY, March 29 (HealthDay News) -- The drugs azacitidine and lenalidomide provide a highly effective combination treatment for bone marrow cancer, according to the results of a new study.

The phase 1 study, which was funded by the U.S. National Institutes of Health, included 18 higher-risk patients, median age 68, with myelodysplastic syndromes (MDS). In people with this cancer (which is similar to leukemia), stem cells fail to mature into healthy red blood cells, white blood cells or platelets. This leads to infection, anemia and bleeding complications.

The patient response rate to the combined drug treatment was 67 percent, and the treatment was well-tolerated. The combined treatment had a better response rate and remission rate than either drug used alone.

This is the first time that two U.S. Food and Drug Administration-approved drugs have been combined for the treatment of MDS. The findings were published online March 29 in the Journal of Clinical Oncology.

"This combination was so successful, it's being incorporated into the next nationwide MDS study, as well as international studies," study author Dr. Mikkael Sekeres, of the Taussig Cancer Institute at the Cleveland Clinic, said in a news release.

About 15,000 people are diagnosed with MDS each year in the United States, and about 60,000 are living with the disease. MDS primarily affects older adults.

More information

The American Cancer Society has more about myelodysplastic syndromes.



-- Robert Preidt



SOURCE: Cleveland Clinic, news release, March 29, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Stem Cell, Bone Marrow Transplants Both Benefit Leukemia Patients
2. Stem cell breakthrough: Bone marrow cells are the answer
3. Bone Marrow Transplants May Cure Sickle Cell in Adults
4. Mayo Clinic Proceedings: Researchers find evidence of survival gains in bone marrow disease
5. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
6. HIV Hides Out in Bone Marrow Cells
7. University of Michigan scientists discover bone marrow can harbor HIV-infected cells
8. Fewer platelets could be used for some cancer and bone-marrow transplantation patients
9. Autologous Bone Marrow Stem Cells Transplant into Parkinson's Disease Patients is Safe and May Improve Their Quality of Life
10. Vertebroplasty: Integral to treating back pain in blood marrow cancer patients
11. Targeted therapy prolongs life in patients with HER2-positive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... Jacksonville, Florida (PRWEB) , ... April 27, 2017 , ... ... qualified candidates. But they will rapidly reject an outdated healthcare executive resume. , “If ... good look at your executive resume and wondering if it’s as ready as you ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... North American CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication ... 60,000 North American professional caregivers for the prestigious award each year – identifying ...
(Date:4/27/2017)... ... ... Offering the purest product of its kind, Swissx Labs AG has launched ... the market has seen before. Swissx uses proprietary strains of hemp plants grown in ... for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. Learn ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an ... it has completed a round of funding to accelerate its growth strategies. The ... Granite Capital is a growth equity firm focused on investments in healthcare and ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: